An Open Label, Phase II Trial of BKM120 in Cancers With PIK3CA Activating Mutations.

Trial Profile

An Open Label, Phase II Trial of BKM120 in Cancers With PIK3CA Activating Mutations.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2015

At a glance

  • Drugs Buparlisib (Primary)
  • Indications Breast cancer; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Head and neck cancer; Lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours; Uterine cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Sep 2015 Status changed from discontinued to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
    • 24 Jan 2013 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 19 Nov 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top